Last reviewed · How we verify
CT-P16
CT-P16 is a monoclonal antibody that binds to and blocks programmed death ligand 1 (PD-L1), enhancing anti-tumor immune responses by releasing the inhibition of T cells.
CT-P16 is a monoclonal antibody that binds to and blocks programmed death ligand 1 (PD-L1), enhancing anti-tumor immune responses by releasing the inhibition of T cells. Used for Non-small cell lung cancer, Urothelial carcinoma.
At a glance
| Generic name | CT-P16 |
|---|---|
| Also known as | bevacizumab |
| Sponsor | Celltrion |
| Drug class | PD-L1 inhibitor |
| Target | PD-L1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
CT-P16 is a PD-L1 inhibitor developed as a biosimilar or follow-on biologic to atezolizumab. By blocking the interaction between PD-L1 on tumor cells and PD-1 on T cells, it restores T cell-mediated anti-tumor immunity. This mechanism allows the immune system to recognize and attack cancer cells that would otherwise evade immune surveillance.
Approved indications
- Non-small cell lung cancer
- Urothelial carcinoma
Common side effects
- Fatigue
- Decreased appetite
- Nausea
- Immune-related adverse events (pneumonitis, hepatitis, colitis)
Key clinical trials
- Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer (PHASE3)
- Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (PHASE2, PHASE3)
- Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer (PHASE3)
- Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer (PHASE3)
- A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer (PHASE2)
- Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study (PHASE3)
- Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer (PHASE1)
- De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CT-P16 CI brief — competitive landscape report
- CT-P16 updates RSS · CI watch RSS
- Celltrion portfolio CI